DMDG – EU

Booth #5A

October 5–7, 2026Prague, Czech Republic

Taking place in Prague, Czech Republic, from October 5 to 7, 2026, the DMDG-GMP-SPS Joint Meeting 2026 will bring together the DMDG, GMP, and SPS communities. The meeting highlights key scientific topics in ADME, DMPK, and PK/PD, with a dynamic program including Early Career sessions, a Candlelight Lecture, and debates.

DMDG Peptide and Oligonucleotide ADME Workshop 2026 (POW26)

Prague, Czech Republic

  • Sunday, October 4
Hong Zhang 2

Hong Zhang, Ph.D.

Senior Director, DMPK Department, WuXi AppTec

Bridging the Gap: Establishing Predictive In Vitro Models for the In Vivo Metabolism of GalNAc-Conjugated siRNAs

Abstract: GalNAc-conjugated siRNAs have emerged as a promising class of therapeutics with potential across various disease areas. Assessing metabolic stability and biotransformation plays a critical role in the development of these therapies, necessitating the selection of suitable in vitro models. However, many existing in vitro systems fail to accurately predict in vivo metabolic behavior.

Our objective was to systematically identify the optimal models and conditions to simulate in vivo metabolism. We selected Inclisiran, a representative GalNAc-conjugated siRNA, as the model compound. We conducted a thorough comparison of in vitro metabolism across various matrices—including serum, plasma, plated hepatocytes, liver homogenate, S9 fractions, tritosomes, lysosomes, and cytosol—to reflect Inclisiran’s trajectory from injection to the RNA-induced silencing complex (RISC) in hepatocytes.

Our findings demonstrate that rat serum and heparinized plasma closely mirror the in vivo metabolism of Inclisiran by blood nucleases. Furthermore, we optimized several effective hepatic systems to accurately simulate intracellular liver metabolism. To ensure translational relevance, ongoing research focuses on validating these models across different species, particularly human systems. Comparative analyses between human and animal models will help refine species-specific metabolic predictions and reduce discrepancies in drug development.

This research offers valuable insights into the metabolic pathways of Inclisiran, establishing a critical foundation for selecting appropriate in vitro systems. Ultimately, these validated models will facilitate the design and screening of future oligonucleotide therapeutics, thereby advancing the field of RNA-based drug development.

DMDG-GMP-SPS Joint Meeting 2026

Prague, Czech Republic

  • Monday, October 5
  • 1:15pm
Lingling Zhang Photo

Lingling Zhang, Ph.D.

Senior Director, DMPK Department, WuXi AppTec

Radiolabeling Strategies and ADME Insights for Oligonucleotide Therapeutics

Abstract: Radiolabeling techniques are extensively applied in vitro and in vivo animal ADME studies and human mass balance studies of new drugs. For oligonucleotides, a thorough understanding of their absorption, distribution, metabolism, and excretion (ADME) is equally essential during drug development, particularly because clinical radiolabeled human trials are generally not conducted prior to regulatory submission.

This presentation will cover three areas:

  • Current regulatory expectations and industry trends in this area.
  • The unique insights that radiolabeling studies for oligonucleotides can provide to support clinical safety and efficacy considerations.
  • Case studies and experiences learned from our work with these novel modalities.
Discuss Program

Discuss Your Program with Us

Share your development goals and key challenges with our experts to define the right path forward.

Discuss Your Program